Biopharma AI
By
Can Gilead’s $260 Million AI Investment in 2025 — Backed by Strategic AI Initiatives — Accelerate Discovery, R&D, and Commercial Impact in 2026?
Global – December 31, 2025 — Gilead Sciences, Inc. expanded its commitment to artificial intelligence (AI) throughout 2025…
Can Sanofi’s $380 Million AI Investment in 2025 — Bolstered by Strategic Partnerships — Drive Breakthroughs in Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
Can Roche’s $420 Million AI Investment in 2025 — Backed by Strategic AI Deals — Boost Discovery, R&D, and Commercial Advantage in 2026?
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and diagnostics, significantly expanded…
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across…
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Top 10 Pharma Brands of 2025 — Sales Performance, Company Strategy & Market Outlook
The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…
